Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Net Income: 2013-2025

Historic Net Income for Theravance Biopharma (TBPH) over the last 13 years, with Sep 2025 value amounting to $3.6 million.

  • Theravance Biopharma's Net Income rose 128.47% to $3.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.8 million, marking a year-over-year increase of 144.15%. This contributed to the annual value of -$64.0 million for FY2024, which is 15.94% down from last year.
  • According to the latest figures from Q3 2025, Theravance Biopharma's Net Income is $3.6 million, which was down 93.41% from $54.8 million recorded in Q2 2025.
  • In the past 5 years, Theravance Biopharma's Net Income registered a high of $927.1 million during Q3 2022, and its lowest value of -$23.1 million during Q4 2024.
  • In the last 3 years, Theravance Biopharma's Net Income had a median value of -$12.7 million in 2024 and averaged -$6.8 million.
  • In the last 5 years, Theravance Biopharma's Net Income skyrocketed by 4,400.00% in 2022 and then plummeted by 318.54% in 2023.
  • Theravance Biopharma's Net Income (Quarterly) stood at $25.8 million in 2021, then tumbled by 84.90% to $3.9 million in 2022, then crashed by 318.54% to -$8.5 million in 2023, then crashed by 171.45% to -$23.1 million in 2024, then spiked by 128.47% to $3.6 million in 2025.
  • Its Net Income was $3.6 million in Q3 2025, compared to $54.8 million in Q2 2025 and -$13.5 million in Q1 2025.